Rapamycin may help recovery after ischemic stroke in rat study

Researchers found that giving rapamycin immediately after blood flow was restored reduced brain damage and improved recovery in a rat model of ischemic stroke. The findings suggest the FDA-approved drug could one day complement standard stroke treatment, though human studies are still needed.

Why it matters: - Ischemic stroke remains a leading cause of death and long-term disability worldwide. - Many patients still have lasting neurological problems even after doctors restore blood flow. - A treatment that works after recanalization could fill a major gap in current stroke care. - Rapamycin is already FDA-approved, which could make future clinical testing more practical if the results translate to humans.

What happened: - A research team led by Dr. Anna M. Schneider at the University of Oxford tested rapamycin in a rat model of ischemic stroke. - The team worked with researchers from the University of Zurich and the University of Newcastle. - The study was made available online on May 15, 2026 and published in Neuroprotection, Volume 4, Issue 2, on June 1, 2026. - Researchers gave rapamycin immediately after recanalization, meaning after blood flow had been restored. - The experiment aimed to mirror real-world stroke treatment, where patients receive care after arriving at the hospital.

The details: - Rats had blood flow to the brain blocked for 90 minutes before circulation was restored. - One group received intravenous rapamycin immediately after reperfusion. - A control group received no rapamycin. - The team used MRI and neurological tests over the next 3 days to track injury and recovery. - Rapamycin-treated rats developed significantly smaller infarcts than untreated rats. - Rapamycin also improved neurological performance and sensorimotor recovery. - Measurements showed no significant difference in cerebral blood flow between treated and untreated animals. - The study found no significant differences in blood-brain barrier integrity or brain swelling. - The paper’s title was “Post-recanalization administration of rapamycin improves functional outcome and reduces infarct size in a rat model of ischemic stroke.” - The DOI is https://doi.org/10.1002/nep3.70035.

Between the lines: - The result matters because many earlier stroke studies gave rapamycin before or during ischemia, which is less relevant to hospital treatment. - The benefit appears to come from limiting secondary injury after reperfusion, not from improving circulation. - That suggests stroke recovery may be improved through mechanisms beyond restoring blood flow alone. - The study offers early support for rapamycin as an adjunct therapy, not a replacement for current stroke treatment.

What's next: - The researchers say larger animal studies are needed. - Human clinical trials will be required before rapamycin can be considered for stroke patients. - Longer-term studies are also needed to see whether the 3-day benefits persist. - Future work will need to determine whether the same protection appears when treatment is given in clinical settings after recanalization.

The bottom line: - Rapamycin helped rats recover better after ischemic stroke when given after blood flow returned, pointing to a possible new add-on therapy for stroke care.